3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Thyroid Neoplasms
1
Prostatic Neoplasms
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pain
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Kidney Neoplasms
1
Hypothyroidism
1
Hepatic Encephalopathy
1
Goiter
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Cancer Pain
1
Breast Neoplasms
1
Interventions
Paclitaxel
9
Carboplatin
6
Cisplatin
5
Hyperthermic Intraperitoneal Chemotherapy
4
Oxaliplatin
3
Fluorouracil
3
Cytoreduction Surgical Procedures
3
Bevacizumab
3
nintedanib
2
Mitomycin
2
Leucovorin
2
Laparoscopy
2
Gemcitabine
2
Folfox protocol
2
Docetaxel
2
vandetanib
1
talimogene laherparepvec
1
strattice
1
sodium thiosulfate
1
poly(I).poly(c12,U)
1
pembrolizumab
1
olaparib
1
nilotinib
1
liposomal doxorubicin
1
lentiviral minigene vaccine of COVID-19 coronavirus
1
farletuzumab
1
enzastaurin
1
catumaxomab
1
birinapant
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Peritoneal Neoplasms
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts